MPI-CDG — phosphomannose isomerase deficiency (OMIM #602579), the second congenital disorder of glycosylation to be described and the only CDG syndrome with an established, effective, and curative small-molecule therapy (CDG Ib), caused by biallelic pathogenic variants in MPI (encoding mannose phosphate isomerase, the cytosolic enzyme catalyzing the interconversion of fructose-6-phosphate and mannose-6-phosphate, the committed step supplying mannose-6-phosphate for GDP-mannose synthesis, dolichol-P-mannose production, and the lipid-linked oligosaccharide assembly required for N-linked protein glycosylation) — with enzymatic deficiency producing a selective deficiency of the mannose-6-phosphate substrate for N-glycosylation despite intact downstream glycosylation machinery, creating a potentially remediable glycosylation defect that can be bypassed by exogenous oral mannose supplementation providing mannose-6-phosphate through the hexokinase-mediated phosphorylation of dietary mannose independent of the defective MPI enzyme — manifests with a strikingly distinct clinical phenotype compared to other CDG syndromes: the predominant hepatic-intestinal presentation characterized by hepatomegaly, liver fibrosis progressing to cirrhosis in untreated patients, protein-losing enteropathy with hypoalbuminemia and anasarca, hypoglycemia (hepatic glycogen storage dysfunction from glycoprotein hypoglycosylation), coagulopathy (deficiency of N-glycosylated coagulation factors including antithrombin, protein C, protein S, and factor XI), recurrent vomiting, diarrhea, and gastrointestinal bleeding — without the cerebellar hypoplasia, intellectual disability, or neurological features that characterize most other CDG syndromes, making MPI-CDG the hepatic-intestinal CDG where the neurological outcome is preserved if the diagnosis is made and oral mannose supplementation is initiated before progressive hepatic fibrosis causes irreversible end-stage liver disease. MPI-CDG is biochemically characterized by the Type I CDG transferrin isoform pattern on isoelectric focusing or mass spectrometry, reduced MPI enzyme activity in leukocytes or fibroblasts (typically below 20% of normal), and biallelic pathogenic MPI variants — with the plasma mannose level characteristically reduced (mannose is the direct substrate for MPI and its level reflects the severity of the MPI enzymatic block) and elevated liver enzymes, hypoalbuminemia, and coagulopathy marking the hepatic and gastrointestinal disease burden; importantly, mannose supplementation normalizes plasma mannose and progressively improves glycosylation, hepatic function, coagulopathy, and protein-losing enteropathy in the large majority of treated patients, with long-term resolution of the CDG biochemical phenotype on transferrin analysis in some patients on stable mannose therapy. The estimated incidence of MPI-CDG is substantially lower than PMM2-CDG — fewer than 100 cases reported worldwide — representing a disease where monitoring platform reliability is directly linked to the mannose supplementation therapy monitoring urgency, the hepatic fibrosis and cirrhosis surveillance obligations, the coagulopathy and hypoglycemia management demands, and the protein-losing enteropathy monitoring requirements that together define the clinical course of a treatable CDG syndrome where treatment timing determines whether irreversible hepatic injury develops.
MPI-CDG technology platforms — encompassing the transferrin isoelectric focusing and mass spectrometry platforms establishing the CDG Type I biochemical diagnosis, the MPI enzyme activity assay platforms measuring mannose phosphate isomerase activity in leukocytes or fibroblasts, the plasma mannose level monitoring platforms (reduced in untreated MPI-CDG, normalizing with mannose supplementation — a direct pharmacodynamic biomarker for therapy response), the molecular genetics platforms performing MPI sequencing and deletion/duplication analysis, the hepatic function monitoring platforms (ALT, AST, GGT, albumin, bilirubin, INR, alpha-fetoprotein) tracking hepatic disease severity and mannose therapy response, the hepatic imaging platforms (ultrasound, elastography, MRI) for hepatomegaly, hepatic fibrosis, and portal hypertension surveillance, the coagulation monitoring platforms measuring factor XI, antithrombin, protein C, protein S, and fibrinogen, the protein-losing enteropathy monitoring platforms (serum albumin, alpha-1 antitrypsin clearance, fecal protein loss), the hypoglycemia monitoring platforms (continuous glucose monitoring and plasma glucose surveillance), the liver transplantation coordination platforms for patients presenting with end-stage liver disease before diagnosis (liver transplantation corrects the hepatic MPI deficiency and may reduce CDG severity), and CDG natural history registry and mannose therapy outcome tracking platforms — must maintain the availability and performance standards required by the mannose therapy response monitoring urgency, the hepatic disease surveillance complexity, the coagulopathy and hypoglycemia management demands, and the protein-losing enteropathy monitoring obligations of MPI-CDG. This guide explains why MPI-CDG tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the mannose therapy urgency, hepatic disease surveillance complexity, coagulopathy management demands, and protein-losing enteropathy monitoring obligations of the only treatable CDG syndrome with an effective oral small-molecule therapy.
Why MPI-CDG Tech Platforms Require Specialized Monitoring Attention
MPI-CDG management presents monitoring challenges shaped by the mannose supplementation therapy monitoring urgency, the hepatic fibrosis progression surveillance complexity, the coagulopathy and hypoglycemia management demands, and the protein-losing enteropathy monitoring obligations that define outcomes in the only CDG syndrome with an effective and widely available oral treatment: the mannose supplementation therapy monitoring urgency — oral mannose supplementation at 0.5–1.0 g/kg/day in five to six divided doses is the cornerstone of MPI-CDG treatment, providing mannose for hexokinase-mediated phosphorylation to mannose-6-phosphate independent of the defective MPI enzyme; mannose therapy response monitoring requires frequent plasma mannose levels (targeting a post-dose plasma mannose above 100–200 µmol/L), transferrin CDG analysis at 3-month intervals to document glycosylation normalization, and hepatic function monitoring to document the hepatic response; the hepatic fibrosis progression surveillance complexity — in untreated or late-diagnosed patients, hepatic fibrosis progresses to cirrhosis with portal hypertension, hepatocellular carcinoma risk, and end-stage liver disease requiring transplantation; even treated patients with pre-existing fibrosis require serial hepatic surveillance because mannose therapy arrests but may not fully reverse established fibrosis; the coagulopathy management demands — simultaneous deficiency of procoagulant (factor XI, fibrinogen) and anticoagulant (antithrombin, protein C, protein S) glycoprotein factors creates the same paradoxical thrombotic-hemorrhagic risk seen in PMM2-CDG, with hemorrhagic risk from gastrointestinal protein loss and thrombotic risk from portal hypertension complications; and the protein-losing enteropathy monitoring obligation — hypoalbuminemia and anasarca from gastrointestinal protein loss are presenting features of MPI-CDG and the most visible therapeutic response marker when mannose is initiated.
Plasma mannose level monitoring platforms are the primary pharmacodynamic biomarker platforms for mannose supplementation therapy in MPI-CDG — plasma mannose normalization confirms adequate oral mannose delivery, absorption, and systemic bioavailability, and is the most direct measure of therapy adequacy before biochemical glycosylation normalization on transferrin analysis. Plasma mannose is characteristically reduced in untreated MPI-CDG due to the absence of MPI-mediated endogenous mannose-6-phosphate from fructose-6-phosphate; with oral mannose supplementation, plasma mannose rises to supranormal post-dose levels; post-dose plasma mannose above 100 µmol/L is the therapeutic target; a platform failure disrupting plasma mannose monitoring during the dose-titration phase prevents the metabolic dietitian and metabolic physician from determining whether the mannose dose is adequate, resulting in underdosing that perpetuates hepatic glycoprotein hypoglycosylation and ongoing liver injury. Monitor at 1-minute intervals during laboratory hours. Alert immediately.
Transferrin CDG analysis platforms are essential in MPI-CDG for both initial diagnosis and longitudinal treatment response monitoring — the progressive normalization of the Type I CDG transferrin pattern documents the biochemical glycosylation restoration achieved by mannose therapy. The Type I CDG transferrin pattern at diagnosis confirms CDG biochemistry and directs the MPI enzyme activity and molecular testing cascade; with successful mannose therapy, the transferrin pattern normalizes progressively over months to years — a finding unique among CDG syndromes as most have no treatment capable of normalizing glycosylation biomarkers; transferrin CDG analysis at 3-month intervals during the first year of therapy and then 6-monthly thereafter documents treatment response; a platform failure disrupting transferrin CDG monitoring prevents glycosylation normalization documentation and may mask a therapy response plateau signaling dose inadequacy. Monitor at 1-minute intervals during laboratory hours. Alert immediately.
Hepatic function monitoring platforms are critical in MPI-CDG for progressive hepatic fibrosis and cirrhosis surveillance — untreated MPI-CDG progresses to end-stage liver disease, and mannose therapy response in the liver determines whether transplantation-free survival is achievable. ALT, AST, and GGT normalize progressively with mannose therapy; albumin and INR improve as hepatic synthetic function recovers; alpha-fetoprotein provides hepatocellular carcinoma surveillance in patients with established cirrhosis; a platform failure disrupting hepatic function monitoring during mannose therapy obscures the hepatic response signal that determines whether the current therapy dose is adequate or whether dose escalation, additional interventions, or liver transplantation evaluation is needed. Monitor at 1-minute intervals during laboratory hours. Alert immediately.
What to Monitor on a MPI-CDG Care Tech Platform
Plasma Mannose and Transferrin CDG Biomarkers
Monitor plasma mannose level records (plasma mannose as the primary pharmacodynamic biomarker for mannose supplementation therapy; pre-dose (trough) plasma mannose — characteristically reduced in untreated MPI-CDG, reflecting the absence of MPI-mediated endogenous mannose synthesis from fructose-6-phosphate; post-dose plasma mannose — the therapeutic target; peak plasma mannose above 100–200 µmol/L confirming adequate oral mannose absorption; mannose levels 1–2 hours post-dose for peak measurement; mannose level frequency — every 3 months during dose titration, every 6 months during stable therapy; mannose dose and timing documentation; mannose formulation records — mannose powder dissolved in water or juice, given five to six times daily; plasma mannose response trajectories over years of therapy), transferrin CDG analysis records (transferrin isoelectric focusing or mass spectrometry at diagnosis for Type I CDG confirmation; serial transferrin CDG analysis every 3 months during the first year of therapy documenting progressive normalization of the CDG transferrin pattern; transferrin CDG normalization as the biochemical glycosylation restoration endpoint; transferrin CDG analysis in the context of concurrent conditions affecting transferrin glycosylation — iron deficiency, liver disease, pregnancy; the timeline of transferrin CDG normalization — typically over months to years of therapy; patients achieving complete transferrin CDG normalization representing a remarkable outcome in CDG therapeutics), and MPI enzyme activity and molecular genetics records (MPI enzyme activity in leukocytes or fibroblasts — typically below 20% of normal; residual MPI activity correlating with disease severity and mannose supplementation dose requirements; MPI gene sequencing for pathogenic variant identification; family cascade evaluation — siblings at 25% recurrence risk; parental carrier status confirmation; prenatal molecular testing for at-risk pregnancies) — at a 1-minute interval during laboratory hours. Alert immediately.
Hepatic Surveillance and Fibrosis Monitoring
Monitor hepatic function records (ALT and AST at diagnosis and every 3 months during therapy — progressive normalization with mannose supplementation confirming hepatic glycoprotein synthesis restoration; GGT for biliary involvement; albumin — severely reduced in protein-losing enteropathy, progressive recovery with mannose therapy; prealbumin for acute nutritional and synthetic function monitoring; total protein; bilirubin — direct and total; INR for synthetic function; alkaline phosphatase — elevated in biliary and hepatic disease; ammonia in patients with cirrhosis and hepatic encephalopathy), hepatic imaging records (liver ultrasound at diagnosis and every 6 months — hepatomegaly, parenchymal echogenicity, hepatic fibrosis pattern, portal hypertension features including splenomegaly and ascites; transient elastography by FibroScan for non-invasive hepatic fibrosis staging — baseline and 12-monthly during therapy; liver MRI for hepatic parenchymal characterization, HCC surveillance in cirrhotic patients, and hepatic vascular anatomy; CT or MRI for portal vein thrombosis detection and portal hypertension complications; hepatic arterial and portal venous phase imaging for HCC detection; liver biopsy for fibrosis staging — baseline Metavir score and longitudinal assessment of fibrosis regression), hepatocellular carcinoma surveillance records (alpha-fetoprotein at 6-month intervals in patients with established cirrhosis; liver ultrasound at 6-month intervals for HCC nodule detection; cross-sectional imaging for lesion characterization; the emerging HCC risk in MPI-CDG patients with long-standing hepatic disease before diagnosis and treatment), and portal hypertension complication records (upper gastrointestinal endoscopy for esophageal and gastric varices in cirrhotic patients; variceal banding records; propranolol for secondary variceal prophylaxis; ascites management records; hepatic encephalopathy episodes; spontaneous bacterial peritonitis documentation) — at a 1-minute interval during clinical and laboratory hours. Alert immediately.
Coagulation and Hypoglycemia Management
Monitor coagulation factor records (factor XI activity — deficient due to hypoglycosylation; antithrombin activity — deficient, creating hypercoagulable state; protein C and protein S activities — deficient; fibrinogen — structurally and functionally abnormal; PT/INR and aPTT; coagulation factor normalization during mannose therapy — tracking restoration of glycoprotein synthesis; the paradoxical MPI-CDG coagulopathy — simultaneous procoagulant and anticoagulant deficiency creating thrombotic-hemorrhagic risk; thromboembolism documentation — portal vein thrombosis in cirrhotic patients, peripheral venous thromboembolism; hemorrhagic event documentation — gastrointestinal bleeding from varices, mucosal hemorrhage; anticoagulation management records for thromboembolism in the context of complex coagulopathy), hypoglycemia monitoring records (plasma glucose at presentation — hypoglycemia common at diagnosis due to glycoprotein-dependent hepatic glycogen mobilization impairment; fasting glucose tolerance; continuous glucose monitoring in patients with severe or recurrent hypoglycemia; plasma glucose normalization with mannose therapy; hypoglycemia protocol records for illness-associated fasting risk; glucagon and emergency glucose supplementation protocols; avoidance of prolonged fasting; the hypoglycemia mechanism — impaired hepatic glycogenolysis from hypoglycosylation of key glycoproteins in the glycogen storage and mobilization pathway), and illness protocol records (illness-associated metabolic decompensation risk — fever, vomiting, and reduced oral intake precipitate acute hypoglycemia and coagulopathy exacerbation; illness protocols for mannose supplementation continuation, glucose supplementation, and hospitalization triggers; emergency room and hospitalization records during acute illness) — at a 1-minute interval during clinical hours. Alert immediately.
Protein-Losing Enteropathy and Gastrointestinal Monitoring
Monitor protein-losing enteropathy records (serum albumin at diagnosis — frequently severely reduced, often below 20 g/L in classic presentations; progressive albumin normalization during mannose therapy — the most rapidly visible therapeutic response; pre-albumin for acute nutritional monitoring; total protein; alpha-1 antitrypsin clearance test for fecal protein loss quantification before and during mannose therapy; fecal calprotectin for gastrointestinal mucosal inflammation; stool alpha-1 antitrypsin normalization during mannose therapy confirming enteropathy resolution; anasarca and edema documentation and resolution with therapy; protein supplementation records for acute phase of therapy before enteropathy resolves), gastrointestinal endoscopy records (upper gastrointestinal endoscopy for gastric and duodenal mucosal assessment — protein-losing enteropathy in MPI-CDG is associated with mucosal lymphangiectasia in some patients; intestinal biopsy records; small bowel MRI for bowel inflammation and lymphangiectasia characterization; colonoscopy for colonic mucosal assessment; protein-losing enteropathy response to mannose therapy — endoscopic normalization), and nutritional monitoring records (growth anthropometrics — weight, height, weight-for-height; caloric intake; enteral supplementation records; parenteral nutrition records during severe acute phase before enteral tolerance improves; micronutrient monitoring; vitamin deficiency assessment — fat-soluble vitamins in cholestatic hepatic disease; zinc and selenium monitoring; feeding assessment in infants with severe hepatic disease and ascites) — at a 1-minute interval during clinical and laboratory hours. Alert immediately.
Liver Transplantation
Monitor transplant evaluation records (liver transplantation as the definitive intervention for MPI-CDG patients presenting with end-stage liver disease before the MPI-CDG diagnosis is made or before mannose therapy can arrest disease progression; transplant corrects the hepatic MPI deficiency and restores hepatic N-glycosylation; post-transplant glycosylation improvement — transferrin CDG pattern may normalize or improve; the important distinction that liver transplantation is NOT the first-line treatment for MPI-CDG as in most CDG syndromes — because oral mannose provides an effective and non-surgical treatment for hepatic disease in the majority of patients; transplant decision records — when mannose therapy fails to arrest cirrhosis progression, UNOS/EUROTRANSPLANT listing), transplant surgical and perioperative records (organ allocation and transplant coordinator records; perioperative mannose supplementation management; coagulopathy correction perioperatively — complex coagulopathy management in patients with cirrhosis; primary graft function; post-transplant coagulopathy resolution trajectory), and post-transplant monitoring records (post-transplant transferrin CDG analysis — glycosylation improvement documenting hepatic MPI restoration; post-transplant hepatic function normalization; post-transplant protein-losing enteropathy resolution; post-transplant mannose supplementation continuation — extrahepatic MPI deficiency persists; post-transplant immunosuppression monitoring; long-term outcome records) — at a 1-minute interval during clinical hours. Alert immediately.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. MPI-CDG management coordinates across metabolic medicine (transferrin CDG analysis, MPI enzyme activity, plasma mannose monitoring, mannose supplementation dose titration), molecular genetics (MPI sequencing, family cascade, prenatal testing), hepatology (hepatic function monitoring, fibrosis staging, HCC surveillance, portal hypertension management), gastroenterology (protein-losing enteropathy, gastrointestinal endoscopy, variceal management), liver transplant surgery and coordination, hematology (coagulopathy management, thromboembolism treatment), dietetics (mannose supplementation administration, nutritional support, protein supplementation), general pediatrics and internal medicine (illness protocol management, hypoglycemia monitoring), intensive care (acute decompensation management), and CDG patient registry coordination — authentication failures block the integrated multi-platform care coordination that the mannose therapy monitoring urgency, hepatic disease surveillance complexity, coagulopathy management demands, and protein-losing enteropathy monitoring obligations require across the only CDG syndrome with an established oral treatment capable of normalizing glycosylation biomarkers and reversing hepatic disease.
SSL Certificates
Monitor SSL certificate expiry across all transferrin CDG analysis platforms, plasma mannose level monitoring systems, MPI enzyme activity assay platforms, molecular genetics platforms, hepatic function laboratory systems, hepatic imaging platforms, protein-losing enteropathy monitoring systems, coagulation monitoring platforms, hypoglycemia monitoring systems, liver transplant coordination platforms, and MPI-CDG registry systems. Certificate errors disrupt the integrated multi-platform care infrastructure that MPI-CDG management requires across the mannose therapy monitoring urgency, hepatic fibrosis surveillance complexity, coagulopathy management demands, and protein-losing enteropathy monitoring obligations.
HIPAA and Rare Genetic Disease Patient Privacy Considerations
MPI-CDG technology platforms handle highly sensitive PHI encompassing MPI molecular testing results (biallelic variants identifying both parents as obligate carriers with 25% recurrence risk per pregnancy, with genetic counseling records for extended family cascade in a rare disease with fewer than 100 reported cases worldwide), transferrin CDG isoform records (establishing the CDG biochemical diagnosis and monitoring treatment response with implications for insurance coverage of long-term mannose supplementation), plasma mannose level records and mannose supplementation prescriptions (documenting ongoing therapy for an ultra-rare disorder with specialized pharmacy requirements and insurance coverage complexities), hepatic function records documenting hepatic fibrosis and cirrhosis severity (with implications for life and health insurance underwriting and transplant evaluation eligibility), protein-losing enteropathy records (hypoalbuminemia, anasarca, and gastrointestinal protein loss with implications for disability benefit eligibility), coagulation factor deficiency records (antithrombin, protein C, protein S deficiency with implications for surgical planning, anticoagulation management, and thromboembolism insurance), liver biopsy fibrosis staging records (Metavir score with long-term hepatic prognosis implications), HCC surveillance records in cirrhotic patients, and liver transplant evaluation and post-transplant management records.
The extreme rarity of MPI-CDG — fewer than 100 cases reported worldwide — means that any disclosure of the clinical, biochemical, or molecular diagnosis could re-identify the patient within the global CDG patient community, even without direct identifiers. The long-term mannose supplementation therapy requirement creates a prescription record that may appear in pharmacy databases, creating additional re-identification risk through prescription drug record linkage in health insurance databases.
Alerting Strategy for MPI-CDG Tech Platforms
Immediate laboratory-hours alerting for plasma mannose and transferrin CDG analysis platforms: Plasma mannose level monitoring and transferrin CDG analysis platforms require immediate alerting during laboratory hours — plasma mannose is the direct pharmacodynamic biomarker for mannose therapy adequacy, and a failure disrupting plasma mannose measurement during dose titration prevents determination of whether the current mannose dose achieves the therapeutic plasma mannose target.
Immediate laboratory-hours alerting for hepatic function monitoring platforms: ALT, AST, albumin, INR, and bilirubin platforms require immediate alerting during laboratory hours — hepatic function trends are the primary clinical response markers for mannose therapy, and failure disrupting hepatic monitoring obscures the treatment response signal that determines dose adequacy and transplant eligibility.
Immediate clinical-hours alerting for hepatic imaging and fibrosis assessment platforms: Hepatic ultrasound and elastography platforms require immediate alerting during clinical hours for progressive hepatic fibrosis characterization, portal hypertension complication detection, and HCC surveillance in cirrhotic patients.
Immediate clinical-hours alerting for coagulation monitoring and hypoglycemia platforms: Coagulation factor monitoring and glucose monitoring platforms require immediate alerting during clinical hours — simultaneous procoagulant and anticoagulant glycoprotein deficiency and hepatic glycogenolysis dysfunction create concurrent hemorrhagic, thrombotic, and hypoglycemic risks requiring coordinated management.
Immediate clinical-hours alerting for protein-losing enteropathy monitoring platforms: Serum albumin and alpha-1 antitrypsin clearance platforms require immediate alerting during clinical hours — hypoalbuminemia from protein-losing enteropathy is the most visible MPI-CDG presenting feature and the most rapidly reversible manifestation of mannose therapy response.
Immediate 24/7 alerting for liver transplant coordination platforms: Organ offer response windows in pediatric and adult liver transplantation are hours — transplant coordination platforms require 24/7 immediate alerting for patients listed for transplantation due to mannose therapy-refractory hepatic disease.
Sustained-failure alert (10–15 minutes): MPI enzyme activity assay platforms, MPI molecular genetics platforms, family cascade evaluation platforms, prenatal genetic testing platforms, nutritional monitoring systems, MPI-CDG natural history registry platforms, and post-transplant monitoring systems.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms MPI-CDG platform availability from the metabolic medicine centers, hepatology departments, gastroenterology services, liver transplant programs, molecular genetics laboratories, coagulation management services, dietetics programs, and CDG registry coordination centers that serve the MPI-CDG population worldwide.
Status Page for MPI-CDG Care Team Communication
A real-time status page gives metabolic medicine teams monitoring plasma mannose levels and transferrin CDG normalization, hepatologists monitoring liver fibrosis and portal hypertension progression, gastroenterologists managing protein-losing enteropathy and variceal hemorrhage, dietitians administering mannose supplementation and nutritional support, molecular genetics teams performing MPI sequencing and family cascade evaluations, hematologists managing the complex coagulopathy, endocrinologists monitoring hypoglycemia and nutrition, liver transplant surgeons and coordinators managing patients with mannose-refractory hepatic disease, intensive care teams managing acute decompensation, and families administering oral mannose five to six times daily at home — immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in MPI-CDG clinic mannose therapy downtime protocols, hepatology department emergency liver disease management procedures, transplant coordination emergency backup plans, and acute hypoglycemia emergency response protocols.
Vigilmon Setup for MPI-CDG Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Plasma mannose (post-dose pharmacodynamic monitoring) | 1 min | Slack + PagerDuty (lab hours) | | Plasma mannose (trough — pre-dose) | 1 min | Slack + PagerDuty (lab hours) | | Transferrin IEF/MS (CDG diagnosis and therapy response) | 1 min | Slack + PagerDuty (lab hours) | | MPI enzyme activity (leukocytes/fibroblasts) | 1 min | Slack + PagerDuty (lab hours) | | MPI gene sequencing and del/dup analysis | 1 min | Slack + PagerDuty (lab hours) | | Hepatic function (ALT, AST, GGT, albumin, bilirubin) | 1 min | Slack + PagerDuty (lab hours) | | INR and coagulation factors (XI, antithrombin, protein C, S) | 1 min | Slack + PagerDuty (lab hours) | | Serum albumin and prealbumin | 1 min | Slack + PagerDuty (lab hours) | | Alpha-1 antitrypsin clearance (protein-losing enteropathy) | 1 min | Slack + PagerDuty (lab hours) | | Plasma glucose (hypoglycemia monitoring) | 1 min | Slack + PagerDuty (clinical hours) | | Liver ultrasound (hepatomegaly, fibrosis, portal hypertension) | 1 min | Slack + PagerDuty (clinical hours) | | Transient elastography (FibroScan — hepatic fibrosis staging) | 1 min | Slack + PagerDuty (clinical hours) | | Alpha-fetoprotein (HCC surveillance — cirrhotic patients) | 1 min | Slack + PagerDuty (lab hours) | | Liver MRI (HCC characterization) | 1 min | Slack + PagerDuty (clinical hours) | | Upper GI endoscopy (variceal surveillance) | 1 min | Slack + PagerDuty (clinical hours) | | Liver transplant coordination | 1 min | Slack + PagerDuty (24/7) | | Post-transplant hepatic function and immunosuppression | 1 min | Slack + PagerDuty (clinical hours) | | Post-transplant transferrin CDG normalization | 1 min | Slack + PagerDuty (lab hours) | | Nutritional monitoring (growth, micronutrients) | 2 min | Slack (clinical hours) | | Family cascade molecular testing | 2 min | Slack (lab hours) | | Prenatal and preimplantation genetic testing | 2 min | Slack (business hours) | | MPI-CDG registry data transfer | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure plasma mannose monitoring platforms with immediate laboratory-hours alerting — plasma mannose is the direct pharmacodynamic biomarker for mannose supplementation therapy adequacy, and monitoring platform reliability determines whether dose titration is guided by actual mannose bioavailability data
- Add transferrin isoelectric focusing and mass spectrometry platforms with immediate laboratory-hours alerting — the Type I CDG transferrin pattern at diagnosis establishes the CDG biochemistry, and serial transferrin CDG normalization during therapy documents the biochemical glycosylation restoration unique to MPI-CDG among all CDG syndromes
- Configure MPI enzyme activity assay platforms with immediate laboratory-hours alerting — MPI activity below 20% of normal confirms the biochemical diagnosis before or alongside molecular testing
- Add MPI gene sequencing platforms with immediate laboratory-hours alerting for variant identification, family cascade initiation, and prenatal testing eligibility assessment
- Configure hepatic function monitoring platforms (ALT, AST, GGT, albumin, bilirubin, INR) with immediate laboratory-hours alerting — hepatic function trend normalization is the primary clinical response marker for mannose therapy
- Add hepatic imaging platforms (ultrasound, FibroScan elastography, MRI) with immediate clinical-hours alerting for hepatic fibrosis staging, portal hypertension surveillance, and HCC detection in cirrhotic patients
- Configure alpha-fetoprotein platforms with immediate laboratory-hours alerting for HCC surveillance in patients with established cirrhosis
- Add coagulation factor monitoring platforms (factor XI, antithrombin, protein C, protein S, INR) with immediate laboratory-hours alerting for the complex coagulopathy management in MPI-CDG
- Configure serum albumin and protein-losing enteropathy monitoring platforms with immediate laboratory-hours alerting — albumin normalization is the most rapidly visible manifestation of mannose therapy response and the primary short-term treatment monitoring target
- Add alpha-1 antitrypsin clearance platforms with immediate laboratory-hours alerting for fecal protein loss quantification
- Configure plasma glucose monitoring with immediate clinical-hours alerting for hypoglycemia detection and management
- Add upper GI endoscopy platforms with immediate clinical-hours alerting for variceal surveillance and variceal hemorrhage management in cirrhotic patients
- Configure liver transplant coordination platforms with immediate 24/7 alerting for patients listed for hepatic transplantation
- Add post-transplant monitoring platforms (hepatic function, transferrin CDG, immunosuppression) with immediate clinical-hours alerting
- Configure nutritional monitoring platforms with sustained-failure alerting for growth and micronutrient deficiency tracking
- Add family cascade molecular testing platforms with sustained-failure alerting for at-risk sibling presymptomatic diagnosis
- Configure prenatal testing platforms with sustained-failure alerting for reproductive decision support in affected families
- Add MPI-CDG registry data transfer platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all plasma mannose, transferrin CDG, hepatic function, imaging, transplant coordination, and registry platforms
- Add the status page URL to MPI-CDG clinic mannose therapy protocols, hepatology emergency procedures, transplant coordination backup plans, and hypoglycemia emergency protocols
Conclusion
MPI-CDG technology platforms are embedded in clinical decisions where plasma mannose monitoring platform availability for the metabolic dietitian titrating the oral mannose supplementation dose in a 3-year-old with MPI-CDG and persistent elevation of ALT at 148 U/L and serum albumin at 22 g/L eight weeks after initiating mannose therapy — when the platform required to report the post-dose plasma mannose level at 1 hour confirming a peak mannose of only 62 µmol/L, below the 100 µmol/L threshold indicating inadequate mannose bioavailability due to the child consuming the mannose solution with a full meal that reduces absorption kinetics, is unavailable during the dose assessment clinic appointment — prevents the dose optimization that would double the mannose dose, shift the timing to 30 minutes before meals, and achieve the plasma mannose above 120 µmol/L that drives transferrin CDG normalization over the following 6 months; where hepatic fibrosis surveillance platform availability for a 12-year-old with MPI-CDG and established hepatic fibrosis on diagnosis — when the transient elastography platform required to report the liver stiffness measurement of 18.4 kPa confirming progression from Metavir F3 to F4 cirrhosis despite 9 months of mannose supplementation, triggering urgent hepatology consultation for portal hypertension evaluation, variceal endoscopy, and liver transplant assessment, is unavailable during the scheduled annual fibrosis monitoring visit — allows the cirrhosis progression to advance without the clinical response that would redirect management from non-transplant to transplant-track evaluation; and where protein-losing enteropathy monitoring platform availability for a 5-month-old presenting with anasarca, hypoalbuminemia at 16 g/L, ascites, and diarrhea — when the transferrin isoelectric focusing platform required to report the Type I CDG pattern that establishes the CDG biochemical diagnosis and identifies MPI-CDG as the treatable cause of the hepatic-intestinal syndrome is unavailable during the acute diagnostic evaluation — delays the mannose supplementation initiation that could arrest the hepatic fibrosis progression while the infant remains in the 100% reversible phase of disease. A plasma mannose monitoring platform unavailable when mannose bioavailability data is needed to titrate the only effective therapy for MPI-CDG, a hepatic fibrosis surveillance platform down when cirrhosis progression is crossing the transplant threshold, a transferrin CDG analysis platform unavailable when the treatable CDG syndrome diagnosis is waiting to be established — these are not IT incidents. They are clinical crises in the management of a uniquely treatable congenital disorder of glycosylation where early diagnosis and mannose therapy adequacy determine whether a child progresses to end-stage liver disease requiring transplantation or achieves long-term hepatic function normalization and transferrin CDG pattern resolution through oral supplementation therapy.
Uptime monitoring gives MPI-CDG tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to metabolic medicine centers, hepatology departments, gastroenterology services, liver transplant programs, molecular genetics laboratories, hematology departments, dietetics programs, and compliance auditors that platform operational reliability matches the mannose therapy monitoring urgency, hepatic fibrosis surveillance complexity, coagulopathy management demands, and protein-losing enteropathy monitoring obligations of modern MPI-CDG care.
Start monitoring your MPI-CDG care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #MPICDG #CDG #CongenitalDisorderOfGlycosylation #CDGIb #MPI #phosphomannoseIsomerase #mannoseSupplementation #hepaticCDG #proteinLosingEnteropathy #hepaticFibrosis #coagulopathy #hypoglycemia #liverTransplant #glycosylation #transferrinCDG #rareDisease #metabolicDisease #HIPAA #healthtech #digitalhealth #uptime #sre